看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 5.2x - 5.8x | 5.5x |
| Historical Pb Multiple | 1.7x - 4.1x | 2.6x |
| Fair Value | ₪0.016 - ₪0.017 | ₪0.016 |
| Upside | -13.8% - -4.7% | -9.3% |
| Benchmarks | - | Full Ticker |
| Entera Bio Ltd. | - | NasdaqCM:ENTX |
| Pluri Inc. | - | TASE:PLUR |
| XTL Biopharmaceuticals Ltd. | - | TASE:XTLB |
| BioLineRx Ltd. | - | TASE:BLRX |
| Scinai Immunotherapeutics Ltd. | - | NasdaqCM:SCNI |
| Can-Fite BioPharma Ltd. | - | TASE:CANF |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| ENTX | PLUR | XTLB | BLRX | SCNI | CANF | |||
| NasdaqCM:ENTX | TASE:PLUR | TASE:XTLB | TASE:BLRX | NasdaqCM:SCNI | TASE:CANF | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | -7.3% | 17.1% | 53.0% | 84.8% | 150.6% | 24.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -11748.8% | -33950.1% | -2295.7% | -396.7% | -132.6% | -1229.8% | ||
| Prior Fiscal Year | NA | -9867.9% | NA | -1262.8% | NA | -1255.9% | ||
| Latest Fiscal Year | -5271.3% | -6407.4% | NA | -31.9% | NA | -1027.5% | ||
| Latest Twelve Months | -5271.3% | -2929.2% | -2295.7% | -31.9% | 1038.9% | -1105.1% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -103.8% | -193.4% | -30.3% | -94.5% | -634.0% | -186.5% | ||
| Prior Fiscal Year | -80.3% | -130.5% | -28.9% | -189.2% | -1180.4% | -107.9% | ||
| Latest Twelve Months | -103.3% | -902.9% | -25.7% | -69.1% | 93.9% | -157.6% | ||
| Next Fiscal Year | 397.9% | 199.7% | 194.9% | -140.7% | 100.1% | -369.4% | ||
| Two Fiscal Years Forward | -53.5% | 87.3% | 66.1% | 478.1% | 53.1% | 23.7% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 406.5x | 42.9x | 224.1x | 0.3x | 4.2x | 22.3x | ||
| Price / LTM EPS | -7.7x | -1.5x | -9.8x | -1.1x | 0.4x | -2.0x | ||
| Price / Book | 9.1x | -3.6x | 1.8x | 0.7x | 0.2x | 6.0x | ||
| Price / Fwd Book | -3.1x | 0.2x | 0.1x | 4.4x | -0.1x | -8.1x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -3.6x | 0.7x | 9.1x | |||||
| Historical P/B Ratio | 1.7x | 2.6x | 4.1x | |||||
| Selected P/B Multiple | 5.2x | 5.5x | 5.8x | |||||
| (x) Book Value | 2 | 2 | 2 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | ENTX | PLUR | XTLB | BLRX | SCNI | CANF | |
| Value of Common Equity | 77 | 31 | 10 | 10 | 2 | 15 | |
| (/) Shares Outstanding | 45.4 | 7.8 | 881.4 | 2,232.6 | 0.9 | 3,105.9 | |
| Implied Stock Price | 1.69 | 3.95 | 0.01 | 0.00 | 2.20 | 0.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 0.27 | 0.27 | 0.27 | 1.00 | 0.27 | |
| Implied Stock Price (Trading Cur) | 1.69 | 14.69 | 0.04 | 0.02 | 2.20 | 0.02 | |
| Trading Currency | USD | ILS | ILS | ILS | USD | ILS | |
| FX Rate to Reporting Currency | 1.00 | 0.27 | 0.27 | 0.27 | 1.00 | 0.27 | |